CCHT(000661)2024-03-25 08:56Group 1: Financial Performance - The company achieved a revenue of 14.566 billion yuan in 2023, representing a year-on-year growth of 15.35% [4] - The net profit attributable to shareholders was 4.532 billion yuan, with a year-on-year increase of 9.47% [4] - R&D investment reached 2.419 billion yuan, showing a growth of 45.46% compared to the previous year [4] Group 2: Product Sales and Market Strategy - The sales proportion of long-acting growth hormone products reached approximately 29% in 2023 [2] - The company plans to enhance product innovation and internationalization strategies to drive future growth [2] - The company aims to increase the sales proportion of long-acting growth hormone to 35% in 2024 [16] Group 3: Shareholder Concerns and Corporate Governance - Investors expressed concerns regarding the significant stock reduction by major shareholders, questioning the impact on shareholder returns [1] - The company has committed to fulfilling disclosure obligations regarding share repurchases and major shareholder actions [2] - There is a call for the company to consider increasing dividends to boost investor confidence [2] Group 4: Future Outlook and Challenges - The company is focusing on reducing reliance on single products and enhancing its R&D capabilities to mitigate risks [2] - Concerns were raised about the impact of declining birth rates on the sales of growth hormone products [13] - The company is exploring potential mergers and acquisitions to strengthen its market position [12]